Molbio Diagnostics Ltd
Molbio Diagnostics Ltd (MOLBIO) last reported results for the quarter ended Jun 2026, with sales of ₹408 crore and net profit of ₹53 crore. The stock last traded at ₹1,498, a market capitalisation of ₹17,262 crore, on a P/E of 69.2. Over the past 52 weeks the stock has ranged between ₹926 and ₹1,687. Figures are as of 6 Oct 2026 and are not real time.
Molbio Diagnostics Ltd share price and key metrics
- Current price
- ₹1,498
- Market cap
- ₹17,262 cr
- Stock P/E
- 69.2
- ROE
- 15.6%
- ROCE
- 18.5%
- Dividend yield
- 0.00%
- 52w high / low
- 1687/926
Metrics as of 6 Oct 2026. Not real time.
Track Molbio Diagnostics Ltd
Cruxal reads every Molbio Diagnostics Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Molbio Diagnostics Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 42%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 10%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 16%
- Last Year
- 16%
Molbio Diagnostics Ltd quarterly results
| ₹ crore | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 100 | 561 | 408 |
| Expenses | 116 | 402 | 308 |
| Operating profit | -16 | 159 | 101 |
| OPM % | -16% | 28% | 25% |
| Other income | 1 | 5 | 3 |
| Interest | 4 | 12 | 11 |
| Depreciation | 12 | 20 | 17 |
| Profit before tax | -31 | 132 | 76 |
| Tax % | -23% | 27% | 31% |
| Net profit | -24 | 96 | 53 |
| EPS (₹) | -10.51 | 8.06 | 5.21 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Molbio Diagnostics Ltd annual results
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 837 | 1,020 | 1,446 |
| Operating profit | 234 | 260 | 320 |
| OPM % | 28% | 26% | 22% |
| Net profit | 84 | 139 | 164 |
| EPS (₹) | 452.37 | 64.34 | 14.77 |
TTM is the trailing twelve months to the most recent quarter.
Molbio Diagnostics Ltd balance sheet
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 2 | 2 | 11 |
| Reserves | 821 | 966 | 1,158 |
| Borrowings | 184 | 147 | 450 |
| Other liabilities | 211 | 346 | 496 |
| Total liabilities | 1,218 | 1,461 | 2,115 |
| Fixed assets | 289 | 290 | 536 |
| CWIP | 2 | 27 | 11 |
| Investments | 6 | 46 | 6 |
| Other assets | 921 | 1,099 | 1,562 |
| Total assets | 1,218 | 1,461 | 2,115 |
As reported by the company. Total assets equal total liabilities by construction.
Molbio Diagnostics Ltd cash flow
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operations | 10 | 287 | 50 |
| Cash from investing | -45 | -123 | -54 |
| Cash from financing | -32 | -26 | 276 |
| Net cash flow | -67 | 138 | 273 |
| Free cash flow | -7 | 232 | 1 |
| CFO / operating profit | 23% | 141% | 38% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Molbio Diagnostics Ltd operating ratios
| Per year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | — | 21% | 18% |
| Debtor days | 186 | 97 | 103 |
| Inventory days | 338 | 384 | 285 |
| Days payable | 101 | 203 | 126 |
| Cash conversion cycle | 423 | 278 | 261 |
| Working capital days | 200 | 128 | 116 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Molbio Diagnostics Ltd shareholding pattern
| % held | Aug 2026 |
|---|---|
| Promoters | 41.29% |
| FIIs | 1.51% |
| DIIs | 16.36% |
| Government | 0.02% |
| Public | 40.83% |
| No. of shareholders | 2,33,544 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Molbio Diagnostics Ltd corporate filings
- Certificate under Regulation 74(5) of the SEBI(Depositories and Participants)Regulations, 2018 for the quarter ended September 30,2026.Company Updatelow impact
- Molbio Diagnostics Limited discloses acquisition of 23.78 lakh equity shares of Face Value Rs. 1 each, representing 2.06% of total share capital, at a date of September 30, 2026.Insider Trading / SASTmedium impact
Cruxal's analysis: Molbio Diagnostics Limited has announced the acquisition of approximately 23.78 lakh…
Read the full analysis - Intimation of Closure of Trading Window for the Quarter ended September 30,2026.Insider Trading / SASTlow impact
- Molbio Diagnostics Limited announces re-appointment of Cost Auditor for FY 2026-27Otherslow impact
Cruxal's analysis: Molbio Diagnostics Limited has formally announced the re-appointment of M/s. K. S…
Read the full analysis - India Business Excellence Fund III reduces stake in Molbio Diagnostics Limited by 2.60% via open market saleInsider Trading / SASTmedium impact
Cruxal's analysis: Molbio Diagnostics Limited has seen a significant divestment by a major institutional…
Read the full analysis - India Business Excellence Fund III reduces stake in Molbio Diagnostics Limited by 30 lakh sharesInsider Trading / SASTmedium impact
Cruxal's analysis: Molbio Diagnostics Limited has reported a divestment by a significant shareholder, India…
Read the full analysis - India Business Excellence Fund III reduces stake in Molbio Diagnostics Limited by 30 lakh sharesInsider Trading / SASTmedium impact
Cruxal's analysis: India Business Excellence Fund III has divested 30 lakh equity shares of Molbio…
Read the full analysis - Molbio Diagnostics schedules analyst and investor meeting for September 22, 2026Company Updatelow impact
Cruxal's analysis: Molbio Diagnostics has announced an analyst and investor meeting scheduled for Tuesday…
Read the full analysis - Molbio Diagnostics Q1 FY27 Earnings Call Highlights: Revenue of 408 crore, 25% EBITDA Margin, and Strategic Focus on Global Expansion and New Disease AssaysCompany Updatehigh impact
Cruxal's analysis: Molbio Diagnostics Limited reported Q1 FY27 consolidated revenue of 408 crore with an…
Read the full analysis - Molbio Diagnostics Ltd announces change of Corporate Identification Number (CIN)Company Updatelow impact
Cruxal's analysis: The company has issued a formal intimation regarding a change in its Corporate…
Read the full analysis - Molbio Diagnostics Limited releases audio recording of Q1 FY2027 earnings callCompany Updatelow impact
Cruxal's analysis: Molbio Diagnostics Limited has formally uploaded the audio recording of its earnings…
Read the full analysis - Molbio Diagnostics Reports Q1 FY27 Financial Results with Revenue of 411.5 crore and PAT of 52.7 croreCompany Updatehigh impact
Cruxal's analysis: Molbio Diagnostics Limited reported a strong start to FY27 with total income of 411.5…
Read the full analysis - Molbio Diagnostics Limited Reports Q1 FY2027 Financial Results with Revenue of 408 crore and Net Profit of 53 croreCompany Updatehigh impact
Cruxal's analysis: Molbio Diagnostics Limited has released its unaudited financial results for the quarter…
Read the full analysis - Molbio Diagnostics releases press release for the quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Molbio Diagnostics has filed a press release regarding its financial performance for the…
Read the full analysis - Molbio Diagnostics Reports Q1 FY2027 Financial Results with Significant YoY Revenue GrowthBoard Meetinghigh impact
Cruxal's analysis: Molbio Diagnostics Limited reported standalone revenue from operations of 399.38 crore…
Read the full analysis - Molbio Diagnostics Reports Q1 FY2027 Financial Results with Significant YoY Revenue GrowthResulthigh impact
Cruxal's analysis: Molbio Diagnostics Limited reported standalone revenue from operations of 399.38 crore…
Read the full analysis - Molbio Diagnostics Limited schedules Q1 FY27 earnings conference call for September 08, 2026Company Updatelow impact
Cruxal's analysis: Molbio Diagnostics Limited has announced an earnings conference call to discuss its…
Read the full analysis - Molbio Diagnostics Limited schedules Board Meeting for September 05, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Molbio Diagnostics Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis - Molbio Diagnostics Limited designates Compliance Officer under SEBI Insider Trading RegulationsOtherslow impact
Cruxal's analysis: Molbio Diagnostics Limited has formally designated Mr. Darshan Raghunath Karekar as the…
Read the full analysis - Intimation of Closure Trading Window as per SEBI (Prohibition of Insider Trading) Regulations, 2015Insider Trading / SASTlow impact
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.